Unknown

Dataset Information

0

Real-world Data From the Swiss Lenalidomide in MDS del(5q) (SLIM)-Registry Identify New Chances and Challenges in Lenalidomide Treatment of Patients With MDS del(5q).

ABSTRACT:

SUBMITTER: Rufer A 

PROVIDER: S-EPMC9208896 | biostudies-literature |

REPOSITORIES: biostudies-literature

Json Xml

Similar Datasets

Unknown Lenalidomide induces ubiquitination and degradation of CK1α in del(5q) MDS.
| S-EPMC4853910 | biostudies-literature
Unknown TP53 suppression promotes erythropoiesis in del(5q) MDS, suggesting a targeted therapeutic strategy in lenalidomide-resistant patients.
| S-EPMC3791697 | biostudies-literature
Transcriptomics Differential response to Lenalidomide from WT and RUNX1-KO MDS-L del(5q) cells
2020-01-28 | GSE126265 | GEO
Unknown Extended survival and reduced risk of AML progression in erythroid-responsive lenalidomide-treated patients with lower-risk del(5q) MDS.
| S-EPMC4017258 | biostudies-literature
Unknown Clinical characteristics and outcomes according to age in lenalidomide-treated patients with RBC transfusion-dependent lower-risk MDS and del(5q).
| S-EPMC5485496 | biostudies-literature
Unknown Age-related inflammatory bone marrow microenvironment induces ineffective erythropoiesis mimicking del(5q) MDS.
| S-EPMC5886057 | biostudies-literature
Unknown Identification of Lenalidomide Sensitivity and Resistance Mechanisms in Non-Del(5q) Myelodysplastic Syndromes.
| S-EPMC7246771 | biostudies-literature
Proteomics Lenalidomide induces ubiquitination and degradation of casein kinase 1A1 in del(5q) MDS
2015-01-26 | MSV000079014 | MassIVE
Unknown Lenalidomide does not increase AML progression risk in RBC transfusion-dependent patients with Low- or Intermediate-1-risk MDS with del(5q): a comparative analysis.
| S-EPMC3650492 | biostudies-literature
Unknown Role of casein kinase 1A1 in the biology and targeted therapy of del(5q) MDS.
| S-EPMC4199102 | biostudies-literature